Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET

Neurology

Volumn 46, Issue 5, 1996, Pages 1430-1436

  Tedroff, J ^a   Pedersen, Marie ^a   Aquilonius, S M ^a   Hartvig, P ^a,b   Jacobsson, Gunilla ^b   Langstrom B ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; RACLOPRIDE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE DEGENERATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

AGED; ANTIPARKINSON AGENTS; CARBON RADIOISOTOPES; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PUTAMEN; RACLOPRIDE; SALICYLAMIDES; SYNAPSES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029904201     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.5.1430     Document Type: Article

References (44)

1. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1: 292-296.
2. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Ann Neurol 1988;24:372-378.
3. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:385-389.
4. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modeling of oral levodopa: clinical applications in Parkinson's disease. Neurology 1993;43:367-371.
5. 11C]raclopride binding in the human brain. J Nucl Med 1993;34:609-613.
6. 11C]raclopride binding in healthy young adults and schizophrenic patients, reliability and age effects. Hum Psychopharmacol 1992;7:157-165.
7. 3H]raclopride binding in rat brain. Synapse 1991;9:188-194.
8. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993;13: 350-356.
9. 11C-raclopride and positron emission tomography. J Neurosci 1992;12: 3773-3780.
10. 11C]raclopride in the human brain. Synapse 1994;16:255-262.
11. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(suppl):125-127.
12. Fahn S, Elton RL, and members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: Macmillan Health Care Information, 1987:153-164.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-445.
14. 11C]-L-3,4-dihydroxyphenylalanine (DOPA) in the primate by positron emission tomography. Acta Neurol Scand 1992;85: 166-173.
15. Holte S, Eriksson L, Dahlbom M. A preliminary evaluation of Scanditronix PC 2048-15B scanner. Eur J Nucl Med 1989;15: 719-721.
16. 2 receptor binding in the living human brain by positron emission tomography. Science 1986;231:258-261.
17. Bergström M, Litton J, Eriksson L, Bohm C, Blomqvist G. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr 1982;6:65-372.
18. Benadriem B, Dewey SL, Schlyer DJ, Wolf AP, Volkow ND. Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioning. IEEE Trans Med Imaging 1991;10:216-222.
19. 2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989;9:696-708.
20. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1989;10:740-747.
21. 11C]raclopride binding. J Nucl Med 1993;34:200P.
22. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(suppl 6): S15-S18.
23. 11C]-L-DOPA in Parkinson's disease measured by positron emission tomography: relations to motor response. Acta Neurol Scand 1992;85:95-102.
24. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
25. Sarre S, Herregodts P, Deleu D, et al. Biotransformation of L-DOPA in striatum and substantia nigra of rats with unilateral, nigrostriatal lesion: a microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1992;346:277-285.
26. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
27. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455.
28. Nyberg P, Nordberg A, Wester P, Winblad B. Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's disease. Neurochem Pathol 1983;1: 193-202.
29. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
30. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
31. Zetterström T, Herrera-Marschitz M, Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res 1986;376:1-7.
32. 2-receptors. Neurology 1994;44:1325-1329.
33. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO-B after L-deprenyl (selegiline) withdrawal. Synapse 1994;18:86-93.
34. Wachtel SR, Abercrombie ED. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994;63:109-117.
35. Engberg G, Elebring T, Nissbrandt H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites: effects of locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 1991; 259:841-847.
36. Paterson LA, Jurio AV, Berry MD, Zhu MY. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in rat striatum. J Pharmacol Exp Ther 1991;258: 1019-1026.
37. van Home C, Hoffer BJ, Stromberg I, Gerhardt GA. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-depleted rat striatum. J Pharmacol Exp Ther 1992;236:1285-1292.
38. Agid Y, Javoy F, Glowinsky J. Hyperactivity of DA neurons after partial destruction of nigrostriatal DA system. Nature 1973;245:150-151.
39. Altar A, Marien MR. Preservation of dopamine release in the denervated striatum. Neurosci Lett 1989;96:329-334.
40. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensation after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;7:290-295.
41. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-DOPA therapy. J Pharmacol Exp Ther 1975;195:453-464.
42. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
43. Bellard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
44. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affects rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989; 168:291-298.